Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Systematic Review and Meta-Analysis
ESC Heart Failure · 01.12.2024 · 11 (6) · 3488-3500
DOI: 10.1002/ehf2.14832 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ESC Heart Failure, online erschienen am 15.05.2024. Verfasst von Ran Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Capital Funds for Health Improvement and Research.
Abstract (Originalsprache)
The efficacy and safety of new-generation devices (NGDs) for severe aortic regurgitation (AR) have mostly been based on single-arm studies with limited sample sizes. Our goal was to summarize the current evidence on NGDs and compare the safety and efficacy of ‘off-label’ and ‘on-label’ devices in NGDs. We searched MEDLINE, Embase, Cochrane Library, and Scopus for articles on transcatheter aortic valve replacement in patients with AR. A total of 31 studies that included 1851 patients were identified through April 2023. Among these, 1067 (57.6%) patients received treatment with ‘on-label’ devices (JenaValve and J-Valve). For NGDs, the total device success rate at 30 days was 94.5% (on-label: 97.8%, off-label: 89.9%; P < 0.001), the all-cause mortality was 4.2% (on-label: 2.6%, off-label: 5.1%; P = 0.006), permanent pacemaker implantation (PPI) was 8.8% (on-label: 6.9%, off-label: 18.4%; P < 0.001), and the rate of greater-than-mild paravalvular leak (PVL) was 1.2% (on-label: 0.9%, off-label: 3.8%; P = 0.003). On-label devices showed significantly better safety and efficacy in terms of the success rate, PPI, greater-than-mild PVL, and 30 day mortality than off-label devices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
- Center for Health Systems Research, Sutter Health, Sacramento, CA, USA.
Förderung
- Capital Funds for Health Improvement and Research
Zitieren
APA
Liu, R., Fu, Z., Jiang, Z., Yan, Y., Yao, J., Liu, X., Yan, X., & Song, G. (2024). Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Systematic Review and Meta-Analysis. ESC Heart Failure, 11(6), 3488-3500. https://doi.org/10.1002/ehf2.14832
Vancouver
Liu R, Fu Z, Jiang Z, Yan Y, Yao J, Liu X, et al. Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Systematic Review and Meta-Analysis. ESC Heart Failure. 2024;11(6):3488-3500. doi:10.1002/ehf2.14832
BibTeX
@article{Liu2024,
author = {Liu, Ran and Fu, Zhaolin and Jiang, Zhengming and Yan, Yunfeng and Yao, Jing and Liu, Xinmin and Yan, Xiaowei and Song, Guangyuan},
title = {Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Systematic Review and Meta-Analysis},
journal = {ESC Heart Failure},
year = {2024},
volume = {11},
number = {6},
pages = {3488--3500},
doi = {10.1002/ehf2.14832}
}
EUVIMED